Finch Therapeutics' CP101 Receives FDA's Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile) Infection
Shots:
- The FDA’s BT designation follows P-II PRISM3 study results assessing CP101 vs PBO in patients with recurrent C. difficile
- FDA’s BT designation is granted to the drugs showing clinical improvement over currently available therapy in serious or life-threatening conditions on at least one clinically significant endpoint with benefits of Priority Review and accelerated approval
- CP101 is an oral- qd- drug developed using Finch’s Full-Spectrum Microbiota (FSM) platform- targeted for prevention of recurrent C. difficile infections
Ref: Business Wire | Image: Finch Therapeutics
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com